Croma Pharma
Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 that manufactures premium hyaluronic acid syringes and a comprehensive minimally invasive aesthetics portfolio (fillers, toxins, skin boosters, PDO threads, PRP), serving healthcare professionals, aesthetic clinics, and orthopaedic specialists across more than 80 countries.
- Company typePrivate
- Founded1976
- HeadquartersLeobendorf, Austria
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Croma Pharma does
Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 and headquartered in Leobendorf, Austria, operating in the minimally invasive aesthetics and orthobiologics markets. The company manufactures premium hyaluronic acid syringes and has produced more than 110 million units over its history, with current operations spanning more than 80 countries and 251-500 employees. Its core product portfolio covers the full minimally invasive aesthetics value chain: hyaluronic acid fillers (including the FDA-approved Obagi saypha ChIQ for cheek augmentation under the MACRO Core Technology platform), botulinum toxin, skin boosters (PhilArt), PDO threads, autologous PRP/Fluid-PRF systems, and a consumer skincare line launched in 2026. The company also operates the Clinicore digital SaaS platform for aesthetic clinic management via a joint venture with Medfile, and recently reacquired Synocrom to re-enter the orthopaedics (knee osteoarthritis) segment.
Revenue is generated through five primary streams: one-time B2B product sales to healthcare professionals and aesthetic clinics via a dedicated webshop (cromapharma.shop) and direct sales force; consumer skincare product sales; sales of MDR-certified orthobiologic devices to orthopaedic practitioners; subscription revenue from the Clinicore SaaS platform; and licensing/co-development royalties from strategic partners such as Waldencast/Obagi Medical. Go-to-market blends enterprise field sales with channel partnerships, including the Waldencast/Obagi relationship for US distribution and the ALOHA Program partnerships with US clinic networks (Schweiger Dermatology, ProMD, Aesthetic Record, Moxie, VIO Med Spa, Next Health, It's a Secret Med Spa) to generate real-world clinical evidence. End customers span healthcare professionals and aesthetic practitioners (primary), aesthetic clinics and med spas, orthopaedic specialists, and end consumers. The company is privately held, family-owned, Ecovadis Gold-rated for sustainability, and expanding aggressively across geographies, verticals, and product lines in 2026.
Croma Pharma firmographics
Firmographics- Name
- Croma Pharma
- Legal name
- Croma-Pharma GmbH
- Website
- https://croma.at
- Company type
- Private
- Founded year
- 1976
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 that manufactures premium hyaluronic acid syringes and a comprehensive minimally invasive aesthetics portfolio (fillers, toxins, skin boosters, PDO threads, PRP), serving healthcare professionals, aesthetic clinics, and orthopaedic specialists across more than 80 countries.
- Ownership category
- akta.pro rank
Croma Pharma industry classification
Industry- Product category
- Medical Aesthetics (Hyaluronic Acid Injectables)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where Croma Pharma is headquartered
LocationHeadquarters
- HQ city
- Leobendorf
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Croma Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Aesthetics Product Portfolio Sales: Sales of comprehensive minimally invasive aesthetics portfolio including hyaluronic acid fillers, botulinum toxin, skin boosters, PDO threads, autologous PRP/Fluid-PRF, and skincare products to healthcare professionals and aesthetic clinics globally
- Skincare Consumer Products: Consumer-facing Croma Skincare line launched in 2026, including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED products
- Orthobiologics/Medical Devices: Sales of hyaluronic acid-based medical devices for orthopaedics including Synocrom for knee osteoarthritis treatment, MDR-certified and available in EU and Switzerland
- Clinicore SaaS Platform: Digital platform subscription revenue from Clinicore, an AI-driven SaaS platform for aesthetic clinic management including automated documentation and onboarding tools
- Licensing and Development Partnerships: Technology licensing and co-development partnerships including Waldencast/Obagi Medical for injectable product development utilizing MACRO Core Technology
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Croma Pharma product offering
Product offeringCore offering
Croma-Pharma manufactures and distributes a comprehensive minimally invasive aesthetics portfolio including hyaluronic acid (HA) dermal fillers, botulinum toxin, skin boosters, PDO threads, and autologous PRP/Fluid-PRF treatments, plus an MDR-certified orthobiologic (Synocrom) for knee osteoarthritis. The company sells its products primarily to healthcare professionals and aesthetic clinics through direct B2B sales and a dedicated webshop (cromapharma.shop), and operates the Clinicore AI-driven SaaS platform for aesthetic clinic management alongside a consumer skincare line.
Product overview
Croma-Pharma is a global player in the minimally invasive aesthetics market and leading European manufacturer of hyaluronic acid syringes. The company offers a comprehensive portfolio of aesthetic products including Hyaluronic Acid Fillers, Botulinum Toxin, Skin Boosters (PhilArt), PDO Threads, and Autologous PRP/Fluid-PRP treatments. The portfolio extends to everyday skincare with the Croma Skincare line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED), and has recently expanded into orthopaedics with Synocrom. Beyond products, Croma provides digital infrastructure through the Clinicore SaaS platform and supports healthcare professionals via the cromacare education platform. Products are distributed through the B2B Onlineshop across more than 80 countries.
Differentiator
Problem solved
Functional benefit
Brands
- cromacare: Croma's global framework for all educational activities in aesthetic medicine, empowering healthcare professionals.
- Clinicore
- Croma Skincare
Products and services
- Hyaluronic Acid Filler Premium hyaluronic acid injectable dermal fillers for aesthetic treatments, including the Saypha filler range, manufactured by Croma-Pharma as a leading European producer of HA syringes. Sold to aesthetic physicians, dermatologists, and healthcare professionals globally.
- Botulinum Toxin Neurotoxin-based injectable product for aesthetic treatments targeting dynamic wrinkles. Distributed to healthcare professionals and aesthetic clinics through B2B channels.
- Skin Booster (PhilArt) Biostimulatory injectables, also known as skin boosters, designed to deliver deep skin hydration and improve skin quality. The PhilArt line is Croma-Pharma's biostimulatory injectable product for aesthetic practitioners.
- PDO Threads Polydioxanone (PDO) thread-based aesthetic treatments for skin lifting and rejuvenation procedures, sold to aesthetic practitioners and clinics.
- Autologous PRP / Fluid-PRF Platelet-rich plasma (PRP) and Fluid-PRF aesthetic treatment systems for skin regeneration procedures, sold to healthcare professionals performing regenerative aesthetic treatments.
- Croma Skincare Line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED) Consumer-facing everyday skincare line from Croma-Pharma including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED, formulated with niacinamide, peptides, and plant stem cells. Vegan and dermatologically tested, bridging in-clinic aesthetic treatments with at-home skincare routines for end consumers.
- saypha ChIQ (Obagi saypha ChIQ) FDA-approved injectable hyaluronic acid gel filler for cheek augmentation and midface contour correction, utilizing Croma-Pharma's proprietary MACRO Core Technology. Developed in partnership with Obagi Medical (Waldencast plc) for the US market.
- Synocrom MDR-certified, biologically derived hyaluronic acid product for treating knee osteoarthritis, with three decades of clinical use. Sold to orthopaedic specialists and healthcare professionals in the EU and Switzerland.
- Clinicore Platform Premium digital SaaS platform for aesthetic clinics incorporating AI-driven features for automated treatment documentation and intelligent onboarding tools. Developed in partnership with Medfile and sold to aesthetic clinic operators.
Quantifiable outcome
- Over 110 million hyaluronic acid syringes produced since 1976
- +1 more outcomes
Companies that use Croma Pharma
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Croma Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Croma Pharma partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and flagship.
- Waldencast plc / Obagi MedicalcorePartnership for development and distribution of Obagi saypha ChIQ injectable hyaluronic acid gel filler approved by FDA for cheek augmentation and midface contour correction. Product utilizes Croma's proprietary MACRO Core Technology, expanding Obagi's injectable portfolio in the US market.
- MedfilecoreStrategic joint venture to accelerate Clinicore platform development. Partnership integrates AI-driven features including automated treatment documentation and intelligent onboarding tools into Croma's premium digital SaaS platform for aesthetic clinics.
- ProMD HealthcoreALOHA Program collaboration to conduct real-world clinical evaluation of Obagi saypha MagIQ hyaluronic acid dermal filler across ProMD's 17 multi-state practice locations, collecting standardized data on clinical efficacy and patient experience.
- Schweiger DermatologycoreALOHA Program key partner to conduct Phase 4 clinical study and real-world evaluation of Obagi saypha MagIQ injectable product across Schweiger's national network of practices, with initial activities beginning early 2026.
- It's a Secret Med SpacoreALOHA Program collaboration to evaluate Obagi saypha MagIQ across 15 med spa locations using structured data capture and clinical protocols, translating FDA pivotal trial data into everyday premium med spa practice.
- Aesthetic RecordcoreALOHA Program partnership leveraging Aesthetic Record's EMR, charting, and analytics platform across network of over 9,000 aesthetic clinics to generate real-world evidence for Obagi saypha MagIQ injectable.
- MoxiecoreALOHA Program strategic partner using software, coaching, and operational tools to collect standardized data on filler integration into scalable aesthetic workflows across Moxie's supported med spa network.
- VIO Med SpacoreALOHA Program launch partner conducting real-world clinical evaluations of Obagi saypha MagIQ across VIO's national network of med spa locations, generating evidence on performance and patient outcomes.
- Next HealthcoreALOHA Program partnership for structured multi-site assessment of Obagi saypha MagIQ filler across Next Health's wellness and longevity centers, leveraging integration of injectables with holistic protocols.
- Novaestiq Corp.flagshipNovaestiq Corp. acquired by Waldencast plc as part of Croma's expansion strategy, including launch of Saypha injectables in US under Obagi Medical brand.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Croma Pharma competitors and assessment
Company assessmentBroad incumbents
- AbbVie (Allergan Aesthetics): Owns the Juvéderm HA filler franchise and Botox—the global category leaders in aesthetic injectables. A large public incumbent whose scale and R&D budget dwarf Croma's; directly competes across Croma's core injectable categories.
- SkinCeuticals (L'Oréal Dermatological Beauty): Medical-grade skincare brand owned by L'Oréal. Comparable to Croma Skincare's positioning at the intersection of clinical aesthetics and consumer skincare, and a benchmark for Croma's consumer channel ambitions.
Direct peers
- Galderma: Global dermatology and aesthetics leader with the Restylane HA filler portfolio, Sculptra biostimulator, and Dysport (botulinum toxin). Most direct competitor to Croma's minimally invasive aesthetics portfolio, especially in HA fillers and skin boosters.
- Teoxane: Swiss manufacturer of HA-based dermal fillers (Teosyal range) and skincare. A direct European HA-filler peer with a comparable private, specialty-manufacturer profile and overlapping target customer (aesthetic practitioners).
- Merz Aesthetics: Private German company offering Belotero HA fillers, Xeomin botulinum toxin, and Ultherapy. Closest peer to Croma: a private, European-rooted, mid-sized aesthetics player competing across overlapping injectable categories.
- Sinclair Pharma: European aesthetics company (acquired by Huadong Medicine) with Ellansé biostimulator and HA fillers. A close comparable in size and business model before acquisition—mid-sized European aesthetics player serving the same HCP customer base.
- IBSA (Institut Biochimique SA): Swiss pharma company offering HA-based products (e.g., Profhilo bio-remodelling, Sinovial for joint care). Directly comparable to Croma across both aesthetic injectables and orthobiologics (overlapping with Synocrom).
Emerging players
- Evolus: US aesthetics company focused on botulinum toxin (Jeuveau). A focused competitor in the same minimally invasive aesthetics category as Croma's botulinum toxin product.
- Revance Therapeutics: US aesthetics company with the RHA Collection of HA fillers and Daxxify (long-acting botulinum toxin). Comparable as a focused injectable aesthetics specialist targeting similar HCP customers.
Regional players
- Hugel (Hugel Aesthetics): Korean aesthetics and medical aesthetics player with botulinum toxin (Botulax) and HA fillers. Comparable product portfolio to Croma's, primarily serving APAC but increasingly expanding globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Croma Pharma social profiles
Digital presenceCroma Pharma compliance and trust
Trust signalCompliance1 record
Croma Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Croma Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Croma Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Croma Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Croma Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Croma Pharma
What does Croma Pharma do?
Croma-Pharma manufactures and distributes a comprehensive minimally invasive aesthetics portfolio including hyaluronic acid (HA) dermal fillers, botulinum toxin, skin boosters, PDO threads, and autologous PRP/Fluid-PRF treatments, plus an MDR-certified orthobiologic (Synocrom) for knee osteoarthritis. The company sells its products primarily to healthcare professionals and aesthetic clinics through direct B2B sales and a dedicated webshop (cromapharma.shop), and operates the Clinicore AI-driven SaaS platform for aesthetic clinic management alongside a consumer skincare line.
Is Croma Pharma a public or private company?
Croma Pharma is a private company. It is classified as family owned and is currently operating.
When was Croma Pharma founded?
Croma Pharma was founded in 1976. It employs 251 to 500 people.
Where is Croma Pharma based?
Croma Pharma is headquartered in Leobendorf, Austria, in the Europe region.
How does Croma Pharma make money?
Five revenue lines are on record. Aesthetics Product Portfolio Sales are the primary driver. The others are skincare Consumer Products, orthobiologics/Medical Devices, clinicore SaaS Platform and licensing and Development Partnerships.
Who are Croma Pharma's main competitors?
Broad incumbents on record are AbbVie (Allergan Aesthetics) and SkinCeuticals (L'Oréal Dermatological Beauty). Direct peers are Galderma, Teoxane, Merz Aesthetics, Sinclair Pharma and IBSA (Institut Biochimique SA). Emerging players are Evolus and Revance Therapeutics. Hugel (Hugel Aesthetics) is listed as a regional player.
Does Croma Pharma have an API?
No public API is recorded for Croma Pharma.
What industry is Croma Pharma in?
Croma Pharma's product category is Medical Aesthetics (Hyaluronic Acid Injectables). Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 3841.